

Doctor's Order Sheet

**belantamab mafodotin**  
**1.9 mg/kg - pomalidomide 4 mg -**

**dexamethasone 20/40 mg** Regimen: Cycles 2+ (Part 1)

ARIA Protocol Name: belantamab mafodotin pomalidomide dexamethasone  
Compassionate

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma



CC7810 0601 09 2025

Name: \_\_\_\_\_

HCN: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

**Allergies:**

**No Known**

Date: \_\_\_\_\_ (DD/MONTH/YYYY) Planned Administration Date: \_\_\_\_\_ (DD/MONTH/YYYY)  
Cycle \_\_\_\_\_ of \_\_\_\_\_ **Cycle Duration: 28 days** Date of previous cycle: \_\_\_\_\_ (DD/MONTH/YYYY)

**MAY PROCEED WITH DOSES AS WRITTEN IF:**

- ANC **greater than or equal to**  $1 \times 10^9/L$  and platelets **greater than or equal to**  $50 \times 10^9/L$ , otherwise notify Hematologist
- LFTs and Bilirubin assessed
- Creatinine clearance assessed.
- Ocular examination assessed (Prior to cycles 2-6 then every 3 months and as clinically indicated)

**PREMEDICATIONS:**

Other: \_\_\_\_\_

**HYDRATION/SUPPORTIVE CARE (FOR COMMUNITY PHARMACY):**

- acetylsalicylic acid 81 mg PO** once daily
- preservative-free artificial tears topically** to both eyes 4 times a day continuously
- metoclopramide 10-20 mg PO** every 6 hours as needed
- Other: \_\_\_\_\_

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_ (DD/MONTH/YYYY) Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: \_\_\_\_\_ (DD/MONTH/YYYY) Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Doctor's Order Sheet

**belantamab mafodotin**

**1.9 mg/kg - pomalidomide 4 mg -**

**dexamethasone 20/40 mg** Regimen: Cycles 2+ (Part 2)

ARIA Protocol Name: belantamab mafodotin pomalidomide dexamethasone  
Compassionate

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma



CC7810 0601 09 2025

Weight: \_\_\_\_\_ kg      Height: \_\_\_\_\_ cm      Body Surface Area (BSA) = \_\_\_\_\_

**CHEMOTHERAPY (FOR HOSPITAL PHARMACY):**

**belantamab mafodotin 1.9 mg/kg X weight (kg) = \_\_\_\_\_ mg**

**IV** in 250 mL normal saline over 30 minutes on day 1

**CHEMOTHERAPY (FOR COMMUNITY PHARMACY):**

**dexamethasone 40 mg**

Dose modification: **dexamethasone 20 mg**

**PO** on day 1, 8, 15 and 22

**pomalidomide 4 mg PO** once daily on days 1 to 21

Dose modification: **pomalidomide 3 mg PO** once daily on days 1 to 21

Dose modification: **pomalidomide 2 mg PO** once daily on days 1 to 21

Dose modification: **pomalidomide 1 mg PO** once daily on days 1 to 21

This prescription is NOT eligible for pharmacist prescribing by dispensing pharmacist

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.